Gastroenterology — MCQs

A 32-year-old woman presents with several months of burning substernal chest pain exacerbated by large meals, cigarettes, and caffeine. Her symptoms are worse when she lies supine, especially when sleeping at night. Antacids often improve her symptoms. This patient is at risk for which of the following conditions?

Q909Medium

Routine second look endoscopy in the setting of non-variceal upper GI bleeding is recommended in patients with which of the following characteristics?

Q910Easy

What is the definitive diagnostic marker for acute pancreatitis?

Gastroenterology Indian Medical PG Practice Questions and MCQs

Question 901: Mallory-Weiss syndrome is commonly associated with which of the following patient populations?

A. Chronic alcoholic patients (Correct Answer)
B. Smokers
C. Patients undergoing occupational benzene therapy
D. Patients with bladder carcinoma

Explanation: **Explanation:** **Mallory-Weiss Syndrome (MWS)** is characterized by non-transmural, longitudinal mucosal lacerations at the gastroesophageal junction or gastric cardia. **Why Option A is correct:** The primary pathophysiology involves a sudden, massive increase in intra-abdominal pressure. This is most commonly triggered by **forceful vomiting, retching, or coughing**. Chronic alcoholic patients are the most frequently associated population because they often experience bouts of binge drinking followed by severe vomiting (emesis). Alcohol also acts as a local irritant to the gastric mucosa, making it more susceptible to injury. **Why the other options are incorrect:** * **Option B (Smokers):** While smoking is a risk factor for peptic ulcer disease and esophageal cancer, it does not acutely cause the mechanical pressure changes required for MWS. * **Option C (Benzene therapy):** Benzene exposure is classically associated with hematological malignancies like Acute Myeloid Leukemia (AML), not acute gastrointestinal mucosal tears. * **Option D (Bladder carcinoma):** There is no direct pathophysiological link between bladder cancer and gastroesophageal junction tears. **NEET-PG High-Yield Pearls:** * **Clinical Presentation:** Patients typically present with **painless hematemesis** following an episode of non-bloody vomiting or retching. * **Diagnosis:** The gold standard for diagnosis is **Upper GI Endoscopy**, which reveals longitudinal mucosal streaks. * **Management:** Most cases (80-90%) are self-limiting and stop bleeding spontaneously. Active bleeding is managed endoscopically with epinephrine injection, clipping, or thermal coagulation. * **Distinction:** Do not confuse MWS with **Boerhaave Syndrome**, which is a *transmural* (full-thickness) esophageal perforation presenting with severe chest pain and subcutaneous emphysema (Mackler’s triad).

Question 902: A patient complaining of difficulty of swallowing of solid foods is suffering from all of the following except:

A. Diffuse esophageal spasm
B. Achalasia cardia
C. Esophageal carcinoma
D. Bulbar palsy (Correct Answer)

Explanation: ### Explanation The key to answering this question lies in distinguishing between **mechanical/structural dysphagia** and **neuromuscular (oropharyngeal) dysphagia** [1]. **Why Bulbar Palsy is the Correct Answer:** Bulbar palsy involves the lower motor neurons of the cranial nerves (IX, X, XI, and XII). This leads to **oropharyngeal dysphagia**, which is characterized by difficulty in initiating the swallow and an inability to propel the food bolus from the pharynx into the esophagus. In neuromuscular disorders like bulbar palsy, patients typically experience more difficulty with **liquids** than solids, often leading to nasal regurgitation or tracheal aspiration [1]. **Analysis of Incorrect Options:** * **Esophageal Carcinoma:** This is a classic example of **mechanical obstruction** [1]. It presents with progressive dysphagia, initially for **solids** and later for liquids as the lumen narrows [1]. * **Achalasia Cardia & Diffuse Esophageal Spasm (DES):** These are **motility disorders** of the esophageal body [2]. In these conditions, dysphagia occurs for **both solids and liquids** [2] simultaneously from the onset. Since the question asks which conditions involve difficulty with solids, these are excluded as they definitely involve solid-food dysphagia. **Clinical Pearls for NEET-PG:** * **Solids only:** Suggests a mechanical/structural obstruction (e.g., Peptic stricture, Carcinoma, Esophageal web) [1]. * **Solids and Liquids (simultaneous):** Suggests a motility disorder (e.g., Achalasia, DES, Scleroderma) [2]. * **Liquids > Solids:** Suggests a neurological/oropharyngeal cause (e.g., Bulbar palsy, Myasthenia Gravis) [1]. * **Bird’s Beak appearance:** Classic radiological sign for Achalasia Cardia on Barium Swallow. * **Corkscrew Esophagus:** Classic radiological sign for Diffuse Esophageal Spasm [2].

Question 903: All of the following are true regarding chronic active hepatitis, except?

A. Common in females
B. Progression to cirrhosis is not seen (Correct Answer)
C. Remission with steroids
D. May associate with autoimmune disease

Explanation: Explanation: Chronic Active Hepatitis (CAH), particularly the autoimmune subtype, is a progressive inflammatory condition of the liver. The correct answer is **Option B** because the hallmark of chronic active hepatitis is its potential to progress to **macronodular cirrhosis** and liver failure if left untreated [1]. * **Why Option B is the correct answer:** The statement "Progression to cirrhosis is not seen" is false. In CAH, persistent "piecemeal necrosis" (interface hepatitis) and bridging necrosis lead to progressive fibrosis, eventually resulting in cirrhosis in a significant percentage of patients [1]. * **Why Option A is incorrect:** Autoimmune CAH shows a strong female predilection (female to male ratio of approximately 4:1), typically affecting young to middle-aged women [2]. * **Why Option C is incorrect:** Corticosteroids (e.g., Prednisolone) are the mainstay of treatment [1]. They induce clinical, biochemical, and histological remission in about 80% of patients, often used in combination with Azathioprine [1]. * **Why Option D is incorrect:** CAH is frequently associated with other autoimmune conditions such as Hashimoto’s thyroiditis, Rheumatoid Arthritis, Type 1 Diabetes, and Sjögren’s syndrome [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Serology:** Type 1 CAH is associated with **ANA** (Anti-Nuclear Antibody) and **ASMA** (Anti-Smooth Muscle Antibody). Type 2 is associated with **Anti-LKM1** (Liver Kidney Microsomal) antibodies. * **Histology:** The characteristic finding is **Interface Hepatitis** (inflammatory infiltrate crossing the limiting plate) [1]. * **Hypergammaglobulinemia:** A classic biochemical feature is a selective increase in IgG levels [1].

Question 904: All of the following metabolic disorders may cause chronic or recurrent abdominal pain, except:

A. Acute intermittent porphyria
B. Addison's disease
C. Hypercalcemia
D. Hyperkalemia (Correct Answer)

Explanation: **Explanation:** Abdominal pain is a common manifestation of several metabolic and endocrine disorders. Understanding the underlying pathophysiology is crucial for differentiating these from surgical emergencies. **Why Hyperkalemia is the correct answer:** Hyperkalemia (elevated serum potassium) primarily affects cardiac conduction and neuromuscular excitability. While it can cause muscle weakness or cardiac arrhythmias, it is **not** a recognized cause of chronic or recurrent abdominal pain. In contrast, **Hypokalemia** can cause abdominal symptoms by inducing paralytic ileus. **Analysis of Incorrect Options:** * **Acute Intermittent Porphyria (AIP):** This is a classic "medical" cause of severe abdominal pain. The pain is neurovisceral, often out of proportion to physical findings, and is frequently accompanied by vomiting, constipation, and neuropsychiatric symptoms [1]. * **Addison’s Disease (Adrenal Insufficiency):** Acute adrenal crisis or chronic insufficiency often presents with vague but severe abdominal pain, nausea, and vomiting. This can mimic an "acute abdomen" and is often associated with hyponatremia and hyperkalemia. * **Hypercalcemia:** Known by the classic mnemonic "Stones, Bones, Abdominal Groans, and Psychic Overtones," hypercalcemia causes abdominal pain through increased gastric acid secretion, constipation, or by triggering **acute pancreatitis**. **NEET-PG High-Yield Pearls:** * **Metabolic causes of abdominal pain:** Lead poisoning, C1 esterase inhibitor deficiency (Hereditary Angioedema), Diabetic Ketoacidosis (DKA), and Uremia [2]. * **AIP Diagnosis:** Look for "port-wine colored urine" (due to porphobilinogen) and elevated urinary PBG levels [1]. * **Clinical Tip:** Always consider a metabolic cause if the patient has severe abdominal pain but a "soft," non-tender abdomen on examination.

Question 905: Arias syndrome is also known as:

A. Rotor syndrome
B. Dubin Johnson syndrome
C. Crigler Najjar syndrome type I
D. Crigler Najjar syndrome type II (Correct Answer)

Explanation: **Explanation:** **Crigler-Najjar Syndrome Type II (CNS-II)**, also known as **Arias Syndrome**, is an autosomal dominant disorder characterized by a partial deficiency of the enzyme **UDP-glucuronosyltransferase (UGT1A1)**. This enzyme is responsible for conjugating bilirubin in the liver. In Arias syndrome, enzyme activity is typically <10% of normal, leading to moderate non-hemolytic unconjugated hyperbilirubinemia (bilirubin levels usually 6–20 mg/dL). Unlike Type I, patients with Arias syndrome usually survive into adulthood without neurological damage and respond well to **Phenobarbital**, which induces the remaining enzyme activity. **Analysis of Incorrect Options:** * **Crigler-Najjar Syndrome Type I:** This is a more severe, autosomal recessive condition where UGT1A1 activity is **completely absent**. It presents with very high bilirubin levels (>20 mg/dL) and a high risk of kernicterus. It does *not* respond to Phenobarbital. * **Rotor Syndrome & Dubin-Johnson Syndrome:** These are causes of **conjugated (direct) hyperbilirubinemia**. They involve defects in the storage or excretion of bilirubin into the bile, rather than conjugation defects. Dubin-Johnson is specifically characterized by a "black liver" due to melanin-like pigment deposition. **High-Yield Clinical Pearls for NEET-PG:** * **Phenobarbital Test:** Used to differentiate CNS-I from CNS-II. Bilirubin levels drop significantly in CNS-II (Arias Syndrome) but remain unchanged in CNS-I. * **Gilbert Syndrome:** The most common hereditary hyperbilirubinemia; it involves a mild reduction in UGT1A1 activity (~30% of normal) and presents with intermittent jaundice triggered by stress or fasting. * **Inheritance:** CNS-I is Autosomal Recessive; CNS-II (Arias) is usually Autosomal Dominant.

Question 906: A young male was found to be HBsAg positive and HBeAg negative with normal liver enzymes. What is the next step in management?

A. Lamivudine therapy
B. Lamivudine plus Interferon therapy
C. Interferon therapy
D. Serial monitoring (Correct Answer)

Explanation: ### Explanation The patient in this scenario is a classic example of an **Inactive HBsAg Carrier State**. This clinical phase of Chronic Hepatitis B (CHB) is characterized by the presence of HBsAg for >6 months, HBeAg negativity (with anti-HBe positivity), low or undetectable HBV DNA levels, and **persistently normal ALT/AST levels** [1]. **Why Serial Monitoring is Correct:** According to AASLD and EASL guidelines, patients in the inactive carrier state have a low risk of progression to cirrhosis or hepatocellular carcinoma (HCC). Treatment is **not indicated** because the virus is not actively replicating or causing hepatic injury. The management strategy is **serial monitoring** of ALT and HBV DNA (typically every 6–12 months) to detect potential reactivation (HBeAg-negative chronic hepatitis) [1]. **Why Other Options are Incorrect:** * **Options A, B, and C:** Antiviral therapy (Lamivudine, Tenofovir, or Interferon) is reserved for patients with evidence of **active viral replication** (high HBV DNA) and **active liver injury** (elevated ALT or significant fibrosis on biopsy/elastography) [1]. Treating an inactive carrier provides no clinical benefit and increases the risk of drug resistance (especially with Lamivudine) and unnecessary side effects. **High-Yield Clinical Pearls for NEET-PG:** 1. **Phase Identification:** Normal ALT + HBeAg negative = Inactive Carrier [1]. Elevated ALT + HBeAg negative = HBeAg-negative Chronic Hepatitis (requires treatment). 2. **Treatment Threshold:** Generally, treatment is started if ALT is >2x the upper limit of normal AND HBV DNA is >2,000 IU/mL (in HBeAg-negative) or >20,000 IU/mL (in HBeAg-positive). 3. **HCC Screening:** Even inactive carriers require periodic USG surveillance if they are high-risk (e.g., older age, family history of HCC, or presence of cirrhosis). 4. **Drug of Choice:** While Lamivudine was used historically, **Tenofovir or Entecavir** are now the first-line oral agents due to a high genetic barrier to resistance.

Question 907: Acute hepatocellular failure in a patient with cirrhosis of the liver is most commonly precipitated by which of the following?

A. Upper gastrointestinal bleeding (Correct Answer)
B. Large carbohydrate meal
C. Portal vein thrombosis
D. Intravenous albumin infusion

Explanation: In a patient with compensated cirrhosis, the liver exists in a state of fragile equilibrium. **Upper gastrointestinal (UGI) bleeding** is the most common and potent precipitant of acute-on-chronic liver failure (ACLF). The mechanism is multifactorial: 1. **Hypovolemia:** Massive blood loss leads to decreased hepatic perfusion and ischemic injury to already compromised hepatocytes [1]. 2. **Nitrogen Load:** Blood in the gut is a massive protein load. Bacteria break down this blood into ammonia and other nitrogenous toxins, which are absorbed into the systemic circulation, frequently triggering hepatic encephalopathy [2]. 3. **Infection Risk:** UGI bleeding significantly increases the risk of spontaneous bacterial peritonitis (SBP), further worsening liver function. **Analysis of Incorrect Options:** * **B. Large carbohydrate meal:** While high-protein meals can trigger encephalopathy, carbohydrate meals do not cause hepatocellular failure. In fact, glucose is often administered to prevent hypoglycemia in liver failure. * **C. Portal vein thrombosis (PVT):** While PVT can cause portal hypertension and variceal bleeding, it is a less frequent primary precipitant of acute failure compared to the direct hemodynamic and metabolic insult of an active bleed [3]. * **D. Intravenous albumin infusion:** This is actually a **treatment** for complications of cirrhosis (like SBP or hepatorenal syndrome) as it expands plasma volume and has antioxidant properties [4]. **NEET-PG High-Yield Pearls:** * **Most common cause of UGI bleed in cirrhosis:** Esophageal varices. * **Prophylaxis:** All cirrhotic patients with UGI bleed must receive prophylactic antibiotics (usually Ceftriaxone) to improve survival. * **Other common precipitants of ACLF:** Infections (SBP), alcohol binge, and hepatotoxic drugs (NSAIDs).

Question 908: A 32-year-old woman presents with several months of burning substernal chest pain exacerbated by large meals, cigarettes, and caffeine. Her symptoms are worse when she lies supine, especially when sleeping at night. Antacids often improve her symptoms. This patient is at risk for which of the following conditions?

A. Cardiac ischemia
B. Columnar metaplasia of the distal esophagus (Correct Answer)
C. Mallory-Weiss lesion in the esophagus
D. Squamous cell carcinoma

Explanation: ### Explanation **1. Why the Correct Answer is Right:** The patient presents with classic symptoms of **Gastroesophageal Reflux Disease (GERD)**: substernal burning (heartburn), symptoms triggered by large meals, caffeine, and smoking, and worsening when supine (nocturnal reflux). Chronic exposure of the distal esophageal mucosa to gastric acid leads to a compensatory change where the normal stratified squamous epithelium is replaced by **columnar epithelium** (intestinal metaplasia). This condition is known as **Barrett’s Esophagus**. It is a premalignant condition that significantly increases the risk of **Esophageal Adenocarcinoma**. **2. Why the Incorrect Options are Wrong:** * **A. Cardiac Ischemia:** While GERD can mimic "atypical chest pain," the clear association with meals, posture, and relief with antacids strongly points toward a GI etiology rather than myocardial ischemia. * **C. Mallory-Weiss Lesion:** This refers to longitudinal mucosal lacerations at the gastroesophageal junction, typically caused by forceful vomiting or retching (e.g., in alcoholism or bulimia), not chronic acid reflux. * **D. Squamous Cell Carcinoma (SCC):** While GERD is a major risk factor for Adenocarcinoma, it is **not** a risk factor for SCC. SCC is associated with smoking, alcohol, hot liquids, and achalasia. **3. Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** 24-hour ambulatory pH monitoring is the most sensitive test for GERD. * **Endoscopy:** Indicated in patients with "alarm symptoms" (dysphagia, weight loss, anemia) or long-standing GERD (>5 years) to screen for Barrett’s. * **Histology of Barrett’s:** Presence of **Goblet cells** is the hallmark of intestinal metaplasia. * **Management:** Lifestyle modifications and Proton Pump Inhibitors (PPIs) are first-line. Nissen Fundoplication is the surgical treatment of choice.

Question 909: Routine second look endoscopy in the setting of non-variceal upper GI bleeding is recommended in patients with which of the following characteristics?

A. Rockall score of 2
B. Lesion treated with epinephrine injection alone (Correct Answer)
C. Cardiac disease
D. Renal disease

Explanation: In the management of non-variceal upper gastrointestinal bleeding (NVUGIB), **routine second-look endoscopy** (performing a repeat endoscopy within 24 hours of the initial procedure) is generally **not recommended** for most patients. However, it is indicated when the initial endoscopic therapy is considered suboptimal or carries a high risk of failure. **Why Option B is Correct:** The standard of care for high-risk stigmata (e.g., Forrest Ia, Ib, IIa) is **dual therapy** (e.g., epinephrine injection plus a thermal or mechanical method) [1]. Epinephrine injection alone is insufficient because it primarily works via temporary vasoconstriction and local tamponade, which wears off, leading to a high rate of rebleeding [1]. If a lesion was treated with **epinephrine monotherapy** during the index endoscopy, a second-look endoscopy is warranted to ensure definitive hemostasis or to apply a second modality. **Why Other Options are Incorrect:** * **Option A:** A **Rockall score of 2** is considered low risk. Routine second-look endoscopy is typically reserved for high-risk cases (Rockall score >5-6) if considered at all. * **Options C & D:** While **cardiac and renal diseases** increase the overall morbidity and mortality of the patient, they are not independent indications for a routine second-look endoscopy. Management in these patients focuses on aggressive resuscitation and optimization of comorbidities. **NEET-PG High-Yield Pearls:** * **Forrest Classification:** Essential for predicting rebleeding risk. Forrest Ia (Spurting) and Ib (Oozing) have the highest risk [1]. * **Dual Therapy Rule:** Always combine epinephrine with another modality (clips, cautery, or sclerosants) [1]. * **Proton Pump Inhibitors (PPI):** High-dose IV PPI (80mg bolus followed by 8mg/hr infusion) for 72 hours post-endoscopy significantly reduces rebleeding in high-risk lesions [1]. * **Indications for Repeat Endoscopy:** Only if there is clinical evidence of rebleeding (hematemesis, melena, or hemodynamic instability) or if the initial therapy was inadequate (e.g., monotherapy).

Question 910: What is the definitive diagnostic marker for acute pancreatitis?

A. Lipase (Correct Answer)
B. Serum alkaline phosphatase
C. Increased serum calcium
D. Hyperglycemia

Explanation: **Explanation:** The diagnosis of acute pancreatitis requires at least two of the following three criteria: characteristic abdominal pain, serum amylase or lipase levels ≥3 times the upper limit of normal, and characteristic findings on contrast-enhanced CT [1]. **Why Lipase is the Correct Answer:** Serum **Lipase** is considered the preferred and more definitive biochemical marker compared to amylase. It is more **sensitive and specific** for pancreatic tissue. While amylase levels rise quickly but return to baseline within 3–5 days, lipase remains elevated for 7–14 days, making it more useful for patients who present late. Furthermore, lipase is not elevated in conditions like macroamylasemia or salivary gland disease, which can cause false elevations in amylase. **Why Other Options are Incorrect:** * **B. Serum Alkaline Phosphatase:** This is a marker of cholestasis or biliary obstruction. While it may be elevated in gallstone-induced pancreatitis, it does not diagnose the inflammation of the pancreas itself. * **C. Increased Serum Calcium:** In acute pancreatitis, **hypocalcemia** (low calcium) is typically seen due to saponification of fat in the retroperitoneum. Hypercalcemia is actually a *cause* of pancreatitis, not a diagnostic marker for it. * **D. Hyperglycemia:** This occurs due to transient endocrine dysfunction (decreased insulin release) during an attack, but it is a non-specific finding and is used more for prognostic scoring (e.g., Ranson’s Criteria [1]) rather than diagnosis. **High-Yield Clinical Pearls for NEET-PG:** * **Most Specific Marker:** Lipase. * **Earliest Marker:** Amylase (rises within 2–12 hours). * **Prognostic Indicators:** Hypocalcemia and C-Reactive Protein (CRP >150 mg/L at 48 hours) indicate severe necrotizing pancreatitis. * **Imaging:** CT is the gold standard for assessing complications (necrosis), but is usually not required if enzymes and clinical features are diagnostic [1].

Practice by Chapter

Esophageal Disorders

Practice Questions

Peptic Ulcer Disease

Practice Questions

Inflammatory Bowel Disease

Practice Questions

Irritable Bowel Syndrome

Practice Questions

Malabsorption Syndromes

Practice Questions

Pancreatitis (Acute and Chronic)

Practice Questions

Gastrointestinal Bleeding

Practice Questions

Liver Diseases and Cirrhosis

Practice Questions

Viral Hepatitis

Practice Questions

Biliary Tract Disorders

Practice Questions

Gastrointestinal Motility Disorders

Practice Questions

Gastrointestinal Malignancies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free